Brian Babin criticizes Democrats’ tax policies in recent tweets

Brian Babin criticizes Democrats’ tax policies in recent tweets
Brian Babin U.S. House of Representatives from Texas's 36th district — Official U.S. House Headshot
0Comments

Brian Babin, a U.S. Congressman representing Texas’ 36th district since 2015, recently shared his views and activities through a series of tweets. The posts reflect his political stance and personal experiences, highlighting current events and encounters.

On March 3, 2025, Brian Babin expressed criticism towards the Democratic Party’s policies in a tweet: “Democrats voted to make YOUR life harder! Higher taxes, fewer jobs, and a CUT to the Child Tax Credit! @HouseGOP is fighting to protect YOUR family and future!”

Later that day, Babin tweeted about an encounter with wildlife on his property: “This copperhead thought my property was a snaketuary city… Turns out, we do rapid removals here.” The post included images of the snake removal process.

On March 4, 2025, Babin shared his meeting with Secretary of Defense Pete Hegseth in another tweet: “Great to meet Secretary of Defense Pete Hegseth and hear his report. Morale and recruitment are at an all-time high since President Trump’s election. Our military is BACK and stronger than ever!”



Related

Grace Graham, Deputy Commissioner for Policy, Legislation, and International Affairs of FDA

Cities located in Chambers County saw an FDA inspection of 1 company in Q1

There was one company in a city associated with Chambers County that received an FDA inspection in the first quarter of 2026, according to the U.S. Food and Drug Administration.

Caleb Michaud, Acting Associate Commissioner for External Affairs of FDA

FDA conducts Feb. 12 inspection at AMPAC Fine Chemicals Texas, LLC in La Porte

FDA records show an inspection focused on drug quality assurance took place at AMPAC Fine Chemicals Texas, LLC in La Porte on Feb. 12.

Sara Brenner, Principal Deputy Commissioner at FDA

FDA inspects Octapharma Plasma in Pasadena on Feb. 26, finds no required action

The Food and Drug Administration inspected Octapharma Plasma, Inc. in Pasadena on Feb. 26, reviewing blood and blood products, as reflected in data from the agency’s website.